OS Therapies(OSTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OSTX OS Therapies

Closed 12-23 16:00:00 EST

1.56

-0.04

-2.50%

盘后1.59

+0.03+1.92%

19:59 EST

High1.68	Low1.54	Vol282.41K
Open1.62	D1 Closing1.60	Amplitude8.64%
Mkt Cap54.93M	Tradable Cap34.46M	Total Shares35.21M
T/O443.23K	T/O Rate1.28%	Tradable Shares22.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.56,"timestamp":1766523600000,"preClose":1.6,"halted":0,"volume":282405,"hourTrading":{"tag":"盘后","latestPrice":1.5899,"preClose":1.56,"latestTime":"19:59 EST","volume":7293,"amount":11625.9388,"timestamp":1766537992581},"delay":0,"floatShares":22089100,"shares":35214352,"eps":-0.779604,"marketStatus":"Closed","change":-0.04,"latestTime":"12-23 16:00:00 EST","open":1.62,"high":1.6782,"low":1.54,"amount":443230.80679199996,"amplitude":0.086375,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.779604,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766566800000},"marketStatusCode":5,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.6,"preHourTrading":{"tag":"盘前","latestPrice":1.68,"preClose":1.6,"latestTime":"09:15 EST","volume":5133,"amount":8681.378737500001,"timestamp":1766499334826},"postHourTrading":{"tag":"盘后","latestPrice":1.5899,"preClose":1.56,"latestTime":"19:59 EST","volume":7293,"amount":11625.9388,"timestamp":1766537992581},"volumeRatio":0.638913},"requestUrl":"/m/hq/s/OSTX","defaultTab":"news","newsList":[{"id":"2591641614","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641614?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:29","pubTimestamp":1765805340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 08:29 ET (13:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2591648672","title":"OS Therapies Advances OST-HER2 Osteosarcoma Trial After Positive FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648672?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:01","pubTimestamp":1765796489,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. announced progress in its research and development of OST-HER2, a listeria-based cancer immunotherapy aimed at preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. Following a successful Type C meeting with the FDA, the company reported that data from their ongoing Phase 2b clinical trial, including immune activation biomarker results, may support a Biologics License Application  under the FDA's Accelerated Approval Program. The FDA confirmed that single-arm studies in rare diseases could be considered for this pathway and suggested a confirmatory, randomized study in additional osteosarcoma settings. OS Therapies plans to present new biomarker data from both human and canine studies to the FDA in a forthcoming meeting, with the intent to file BLA documents by the end of January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLMcdLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2590535898","title":"OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590535898","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590535898?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:57","pubTimestamp":1765378623,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has published a corporate presentation highlighting its clinical-stage pipeline and financial summary. The company reports over $300 million invested in its listeria immunotherapy platform, acquired from Advaxis/Ayala in April 2025. The lead program, OST-HER2, targets osteosarcoma and has potential follow-on applications in breast cancer and other solid tumors. The total addressable market for these assets is estimated at $258 billion. The company is targeting accelerated approval for OST-HER2 in human osteosarcoma between April and September 2026, with a projected Priority Review Voucher sale of approximately $160 million. The clinical pipeline also includes candidates for HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer. Current financials show a market cap of $60 million, cash holdings of approximately $4 million, and a monthly cash burn of about $300,000. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLWhznZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139","ADXS"],"gpt_icon":0},{"id":"2590553342","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553342?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:20","pubTimestamp":1765290000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 09:20 ET (14:20 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2589812399","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589812399","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589812399?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:10","pubTimestamp":1764961800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2025 14:10 ET (19:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2589979098","title":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2589979098","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589979098?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:06","pubTimestamp":1764939961,"startTime":"0","endTime":"0","summary":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee Dec 5  - OS Therapies Inc OSTX.A:OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2Source text: [ID:]Further company coverage: OSTX.A ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2589897970","title":"Os Therapies: Scheduled Type C Meeting With United States Food & Drug Administration on December 11, 2025 for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897970?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2589897679","title":"Os Therapies: Scheduled Pre-Marketing Authorisation Application Meeting With UK's Mhra on Dec 8 for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897679?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2589677897","title":"Os Therapies: U.S. FDA Granted a Waiver of Application Fee for Its Bla Filing for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589677897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589677897?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2585836126","title":"OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585836126","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585836126?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:16","pubTimestamp":1763759777,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. reported a net loss of $6.9 million for the quarter, ending with approximately $1.9 million in cash. After the quarter, the company raised $7.8 million from warrant proceeds and has an at-the-market facility in place, extending its cash runway into late 2026. Key business developments included progress toward regulatory filings for OST-HER2, with a UK pre-MAA in December and an FDA Type C meeting on December 11, targeting filings in January 2026. The company also announced plans to spin off OS Animal Health in the first half of 2026, with current shareholders expected to receive direct equity in the new entity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLGbkBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2585367145","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2585367145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585367145?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:22","pubTimestamp":1763731320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 08:22 ET (13:22 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584577159","title":"OS Therapies Is Maintained at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2584577159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584577159?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:19","pubTimestamp":1763489940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 13:19 ET (18:19 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584955457","title":"OS Therapies price target lowered to $17 from $18 at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584955457?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:39","pubTimestamp":1763476765,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer lowered the firm’s price target on OS Therapies (OSTX) to $17 from $18 and keeps a Buy rating on the shares. The fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-price-target-lowered-to-17-from-18-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-price-target-lowered-to-17-from-18-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX"],"gpt_icon":0},{"id":"2584360094","title":"OS Therapies Reports Increased Losses Amid Rising R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584360094","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584360094?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:05","pubTimestamp":1763438720,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) has released its Q3 earnings. Here is a breakdown of the information OS Therapies Incorporated presented to i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-reports-increased-losses-amid-rising-rd-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-reports-increased-losses-amid-rising-rd-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OSTX","BK4139","OS"],"gpt_icon":0},{"id":"2584626506","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626506","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584626506?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:24","pubTimestamp":1763385840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:24 ET (13:24 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584899647","title":"Os Therapies - US Biologics Licensing Application & UK Mhra Marketing Authorization Application Filings for Ost-Her2 Expected in January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584899647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584899647?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:21","pubTimestamp":1763378480,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT16F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2584642692","title":"OS Therapies Q3 EPS $(0.21) Misses $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642692","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642692?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:04","pubTimestamp":1763377475,"startTime":"0","endTime":"0","summary":"OS Therapies Q3 EPS $(0.21) Misses $(0.13) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48893491/os-therapies-q3-eps-0-21-misses-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584064251","title":"OS Therapies Reports Q3 2025 Results and Advances Regulatory Plans for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2584064251","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584064251?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:01","pubTimestamp":1763377288,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL3ddxGx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2577367291","title":"OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2577367291","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577367291?lang=en_us&edition=fundamental","pubTime":"2025-10-22 21:16","pubTimestamp":1761138969,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL472r3y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2577180775","title":"OS Therapies Approves Key Proposals at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577180775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577180775?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:56","pubTimestamp":1761080163,"startTime":"0","endTime":"0","summary":"An announcement from OS Therapies Incorporated ( ($OSTX) ) is now available. On October 21, 2025, OS Therapies Incorporated held its annual meeting...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS","OSTX","BK4097","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ostherapies.com","stockEarnings":[{"period":"1week","weight":-0.0419},{"period":"1month","weight":-0.0643},{"period":"3month","weight":-0.2793},{"period":"6month","weight":-0.0909},{"period":"1year","weight":-0.597},{"period":"ytd","weight":-0.6262}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"AMEX","name":"OS Therapies","nameEN":"OS Therapies"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OS Therapies(OSTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OS Therapies(OSTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OS Therapies,OSTX,OS Therapies股票,OS Therapies股票老虎,OS Therapies股票老虎国际,OS Therapies行情,OS Therapies股票行情,OS Therapies股价,OS Therapies股市,OS Therapies股票价格,OS Therapies股票交易,OS Therapies股票购买,OS Therapies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OS Therapies(OSTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OS Therapies(OSTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}